• Mentice Q2 2026 net sales rose 28.1% organically to SEK 79.6 million; EBITDA swung to a profit of SEK 6.3 million.
• Net loss narrowed to SEK 0.9 million; EPS improved to SEK -0.03.
• Order intake climbed 41.3% organically to SEK 78.6 million; operating cash flow turned positive at SEK 8.3 million.
• For H1 2026, net sales increased 27.3% organically to SEK 141.7 million; net loss narrowed to SEK 17.3 million.
• June 29 brought two orders totaling USD 2.4 million from a top-20 interventional cardiology MedTech group; CEO said the cost base is lower.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mentice AB published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.